Person: GÜL, CUMA BÜLENT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜL
First Name
CUMA BÜLENT
Name
13 results
Search Results
Now showing 1 - 10 of 13
Publication Effects of anti-tumor necrosis factor therapy on kidney function in patients with inflammatory arthritis(Oxford Univ Press, 2013-05-01) Öztürk, Oğuzhan; Yıldız, Abdulmecit; Gül, Cuma Bülent; Dilek, Kamil; GÜL, CUMA BÜLENT; DİLEK, KAMİL; Tıp Fakültesi; 0000-0003-2467-9356; A-7063-2018; EUF-5229-2022Publication Association of morning blood pressure surge (mbps) with left ventricular hypertrophy in autosomal dominant polycystic kidney disease (ADPKD): Across sectional study(Oxford Univ Press, 2016-05-01) Sağ, Saim; Yıldız, Abdulmecit; Ersoy, Alparslan; Ocakoğlu, Gökhan; Oruç, Ayşegül; Güngören, Fatih; Ayar, Yavuz; Gül, Cuma Bülent; Güllülü, Sümeyye; Güllülü, Mustafa; Sağ, Saim; YILDIZ, ABDULMECİT; ERSOY, ALPARSLAN; OCAKOĞLU, GÖKHAN; ORUÇ, AYŞEGÜL; Güngören, Fatih; Ayar, Yavuz; GÜL, CUMA BÜLENT; GÜLLÜLÜ, NAZMİYE SÜMEYYE; GÜLLÜLÜ, MUSTAFA; Tıp Fakültesi; Kardioloji Bölümü; 0000-0002-1114-6051; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0003-2467-9356; AAH-5180-2021; AGF-0767-2022; AAW-9185-2020; AAH-5054-2021; O-9948-2015; AAA-3163-2021; HLG-6346-2023; AAH-4002-2021; A-7063-2018; GSE-0029-2022; HIG-9032-2022; JGR-6552-2023; CTG-8811-2022Publication Irritable bowel syndrome in patients on renal replacement treatment(Oxford Univ Press, 2015-05-01) Aktaş, Nimet; Oruç, Ayşegül; Ersoy, Alparslan; Coşkun, Belkıs Nihan; Gül, Bülent; Yıldız, Abdulmecit; Ayar, Yavuz; Sayılar, Emel Işıktaş; Aktaş, Nimet; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; COŞKUN, BELKIS NİHAN; GÜL, CUMA BÜLENT; YILDIZ, ABDULMECİT; Ayar, Yavuz; Sayılar, Emel Işıktaş; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0002-0710-0923; 0000-0003-0298-4157; AGF-0767-2022; AAH-4002-2021; AAH-5054-2021; O-9948-2015; AAG-7155-2021; GSE-0029-2022; W-2575-2017Publication Efficacy of tacrolimus in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatments(Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2011-01-01) Usta, Mehmet; Ersoy, Alparslan; Gül, Cuma Bülent; Kahvecioğlu, Serdar; Akdağ, İbrahim; Güllülü, Mustafa; Yavuz, Mahmut; Dilek, Kamil; Yurtkuran, Mustafa; ERSOY, ALPARSLAN; GÜL, CUMA BÜLENT; GÜLLÜLÜ, MUSTAFA; YAVUZ, MAHMUT; DİLEK, KAMİL; Yurtkuran, Mustafa; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-0710-0923 ; 0000-0003-2467-9356; AAH-5054-2021; A-7063-2018; JGS-9425-2023; EHM-7377-2022; EUF-5229-2022; EGT-2006-2022OBJECTIVE: We investigated the efficacy and safety of tacrolimus in patients with primary focal segmental glomerulosclerosis (FSGS) resistant to treatment in this study.MATERIAL and METHODS: This prospective study included 9 patients (5 female/4 male) with FSGS resistant to steroids. Their immunosuppressive treatments except corticosteroids were stopped at least six months previously. Tacrolimus (4 mg/day) treatment was administered. The daily urinary protein excretion, serum creatinine, albumin and total cholesterol values were measured before and after treatment.RESULTS: The mean level of daily urinary protein excretion, serum creatinine and serum albumin at the baseline was 4.7 +/- 3.3 g/day, 1.2 +/- 0.6 mg/dL, and 3.5 +/- 0.7 g/dL, respectively. The daily urinary protein excretion significantly reduced from the 1st month of the treatment. At the 6th month, complete remission was achieved in 3 patients (33%) and partial remission in 2 patients (22%). 3 patients were resistant to the treatment. There was no difference in serum albumin, creatinine and cholesterol levels after the treatment when compared to the baseline levels.CONCLU SION: Tacrolimus is a safe and effective treatment in patients with FSGS resistant to treatment. However, the tendency to relapse in all patients who have complete or partial remission when the treatment was withdrawn demonstrates dependence on treatment.Publication Analysis of risk factors associated with urinary tract infection in renal transplant recipients(Oxford University Press, 2015-05-01) Ersoy, Alparslan; Aktaş, Nimet; Oruç, Ayşegül; Gül, Bülent; Yıldız, Abdülmecit; Sayılar, Emel Işıktaş; Ayar, Yavuz; Akalın, Halis; ERSOY, ALPARSLAN; ORUÇ, AYŞEGÜL; GÜL, CUMA BÜLENT; YILDIZ, ABDULMECİT; AKALIN, EMİN HALİS; AKTAŞ, NİMET; SAYILAR, EMEL IŞIKTAŞ; AYAR, YAVUZ; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0001-7530-1279; AAH-5054-2021; AAH-4002-2021; W-2575-2017; AAU-8952-2020; GSE-0029-2022; O-9948-2015; AGF-0767-2022Publication Exclusion reasons of living kidney donor candidates: A single-center experience(Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2014-01-01) Oruç, Ayşegül; Ersoy, Alparslan; Tandoğan, Gülen; Karadayı, Derya; Yıldız, Abdülmecit; Gül, Cuma Bülent; ERSOY, ALPARSLAN; Tandoğan, Gülen; Karadayı, Derya; YILDIZ, ABDULMECİT; GÜL, CUMA BÜLENT; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0003-2467-9356; DYT-8587-2022; A-7063-2018; AAH-5054-2021; FDG-3938-2022; HIG-9032-2022OBJECTIVE: Due to severe organ shortage, living kidney donors are important choices for transplantation. In Muslim countries, such as Turkey, living kidney donors are the main source of donor pool. In the literature, reasons for living donor exclusion are reported from several countries. However, there is no published study that focused on exclusion reasons of donor candidates in Turkey where living kidney transplantation rate is 73.4%. The goal of this retrospective study was to examine the exclusion reasons for donation among living kidney donor candidates at a single center in Turkey.MATERIAL and METHODS : A total 538 adults were evaluated as a living kidney donor candidate between December 1988 and January 2012. Evaluation outcome, exclusion reasons and demographic data were examined from electronic file system and immunology laboratory records.RESULTS: In this period 451 kidney transplantations (38.6% cadaveric, 61.4% living donor) was performed. Overall 261 (48.5%) donor candidates who underwent evaluation could not donate. We were able to find the precise cause of exclusion of 86 donors (33%). Among excluded donor candidates the most common exclusion reason was medical causes (64%) such as diabetes mellitus, low glomerular filtration rate and hypertension.CONCLUSION: Our study suggests that medical causes are significant exclusion reasons for living kidney donation at our center.Publication Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones(Humana Press Inc, 2008-04-01) Öz, Özen; Tuncel, Ercan; Eryılmaz, Salih; Fazlıoğlu, Murat; Gül, Cuma Bülent; Ersoy, Canan; Ocak, Nihal; Dirican, Melahat; Cangür, Şengül; Baran, İbrahim; İmamoğlu, Sazı; ÖZ GÜL, ÖZEN; Tuncel, Ercan; Eryılmaz, Salih; Fazlıoğlu, Murat; GÜL, CUMA BÜLENT; ERSOY, CANAN; Ocak, Nihal; Dirican, Melahat; Cangür, Şengül; Baran, İbrahim; İmamoğlu, Sazı; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0003-2467-9356; AAH-8861-2021; AAG-6985-2021; A-7063-2018; DKQ-6967-2022; EBN-7188-2022; EVM-4069-2022; EXM-4051-2022; A-7063-2018; FOJ-8942-2022; ESK-6562-2022; CHY-1092-2022; CDA-1396-2022Background Thiazolidinediones (TZDs) improve peripheral insulin sensitivity, but the effect on arterial stiffness is less clear. The aim of the present study was to assess the differential effect of pioglitazone or rosiglitazone on arterial stiffness and plasma levels of adiponectin and leptin in patients with type 2 diabetes mellitus. Methods Thirty-five type 2 diabetic subjects were randomly assigned to receive pioglitazone (30 mg/day; n = 14), rosiglitazone (4 mg/day; n = 11), or placebo (medical nutrition therapy; n = 10) for 12 weeks. Changes in plasma glucose, glycosylated hemoglobin, insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, adiponectin, and leptin were evaluated at baseline and after 12 weeks. In parallel, large arterial compliance (C1) and small arterial compliance (C2) were measured at baseline and at the end of treatment period. Results At 12 weeks, the rosiglitazone (P = 0.026) and pioglitazone (P = 0.004) groups had a significant increase from baseline in adiponectin that was not seen in the medical nutrition therapy group. No significant changes in plasma leptin and in C1 and C2 elasticity indexes were observed over the entire study period in any of the treatment groups. Conclusions In this study of patients with type 2 diabetes, treatment with TZDs was associated with a significant improvement in adiponectin levels, although no significant effects were seen on leptin levels and arterial elasticity.Publication Should hemodialysis for renal replacement treatment in hospitalized patients with acute kidney injury be intermittent or continuous(Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2012-01-01) Oruç, Ayşegül; Ersoy, Alparslan; Hoyrazlı, Ayşe; Altınay, Tumay; Aktaş, Nimet; Yıldız, Abdülmecit; Gül, Cuma Bülent; Güllülü, Mustafa; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; Hoyrazlı, Ayşe; Altınay, Tumay; Aktaş, Nimet; YILDIZ, ABDULMECİT; GÜL, CUMA BÜLENT; GÜLLÜLÜ, MUSTAFA; Tıp Faküktesi; İç Hastalıkları Ana Bilim Dalı; Nefroloji Bilim Dalı; 0000-0002-0342-9692; 0000-0003-2467-9356; AAH-4002-2021; AAH-5054-2021; A-7063-2018; EYW-4456-2022; ENP-2775-2022; CCH-7205-2022; HIG-9032-2022; JGS-9425-2023OBJECTIVE: Acute kidney injury (AKI) is a frequent complication of hospitalized patients that is associated with high mortality rate despite all developments. Continuous and intermittent hemodialysis are renal replacement treatment modalities for AKI. In our study we aimed to compare the mortality rates of continuous hemodialysis (CHD) and intermittent hemodialysis (IHD) in hospitalized patients.MATE RIAL and METHODS: Seventy-two patients in Uludag University Hospital diagnosed with AKI in 2008 were enrolled our study. Intermittent or continuous hemodialysis was prescribed by the nephrology counsultant. Data were recorded from patients files retrospectively.RESULTS: Patients were divided into two groups (38 IHD, 34 CHD). Mortality rate (52,6%, 88,2%), oligoanuria (63.2%, 94.1%), positive inotrope therapy (28.9%, 85.3%), sepsis (15.8%, 55.9%), mechanical ventilation (15.8%, 76.5%), rate of surgery (2.6%, 32.4%) and the SOFA score (7.1, 9.5) were significantly higher in CHD group.CONCLUSION: The mortality rate was higher in CHD group, and this might be associated with the greater severity of problems such as hemodynamic instability, multi-organ dysfunction and co-morbid diseases in this group.Publication Increased FGF23 and decreased arterial compliance in early autosomal dominant polycystic kidney disease(Oxford Univ Press, 2013-05-01) Gül, Bülent; Çekiç, Selime; Asiltaş, Burak; Doğan, Selda; Aktaş, Nimet; Oruç, Ayşegül; Doğan, İbrahim; Ersoy, Alparslan; Güllülü, Mustafa; Yurtkuran, Mustafa; Yıldız, Abdülmecit; GÜL, CUMA BÜLENT; Çekiç, Selime; Asiltaş, Burak; Doğan, Selda; Aktaş, Nimet; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; GÜLLÜLÜ, MUSTAFA; Yurtkuran, Mustafa; Tıp Fakültesi; 0000-0003-2589-8585; 0000-0002-0342-9692; AAH-5054-2021; AAH-4002-2021; I-7575-2015; JRG-6380-2023; CHU-7675-2022; EKV-7386-2022; CCH-7205-2022; CSP-3307-2022; EGT-2006-2022Publication Analysis of liver function test abnormalities in kidney transplant recipients(Oxford Univ Press, 2015-05-01) Dizdar, Oğuzhan Sıtkı; Ersoy, Alparslan; Yıldız, Abdulmecit; Ayar, Yavuz; Oruç, Ayşegül; Gül, Cuma Bülent; Dizdar, Oğuzhan Sıtkı; ERSOY, ALPARSLAN; YILDIZ, ABDULMECİT; Ayar, Yavuz; ORUÇ, AYŞEGÜL; GÜL, CUMA BÜLENT; Tıp Fakültesi; Dahiliye Bölümü; 0000-0002-4066-929X; 0000-0003-4607-9220; 0000-0002-0342-9692; 0000-0003-2467-9356; O-9948-2015; D-6213-2013; AAH-4002-2021; AGF-0767-2022; AAH-5054-2021; GSE-0029-2022; A-7063-2018